H3-CoA-20, Inhibitor of E1A binding protein p300;Inhibitor of lysine acetyltransferase 2B, CAS No.rp174191, Inhibitor of E1A binding protein p300;Inhibitor of lysine acetyltransferase 2B

CAS: rp174191 Cat. No.: rp174191

GRADE & PURITY Moligand™

Specifications

Product Name

H3-CoA-20, Inhibitor of E1A binding protein p300;Inhibitor of lysine acetyltransferase 2B, CAS No.rp174191

Note

Moligand™

Spezifikationen & Reinheit

Moligand™

Aktionsart

INHIBITOR

Mechanismus der Wirkung

Inhibitor of E1A binding protein p300;Inhibitor of lysine acetyltransferase 2B

CAS

rp174191

Molekültyp

Peptide

Product Line

Biologische Produkte

Lagerung und Versand

Storage

Room temperature

Zugehörige Ziele (menschlich)

EP300 Tchem Histone acetyltransferase p300 (0 Activities)

Discover Target: EP300

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

KAT2B Tchem Histone acetyltransferase KAT2B (0 Activities)

Discover Target: KAT2B

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Genetische Informationen

• Referenz:
  • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
  • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
  • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
  • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
  • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
  • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
  • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
  • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
  • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
  • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more
  • 11. Toward a confocal subcellular atlas of the human proteome., Molecular & cellular proteomics : MCP, Barbe, Laurent L and 10 more authors.
  • 12. Kinetic properties of polymorphic variants and pathogenic mutants in human cystathionine gamma-lyase., Biochemistry, Zhu, Weidong W, Lin, Alexander A and Banerjee, Ruma R.
  • 13. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway., Carcinogenesis, Hosgood, H Dean HD and 12 more authors.
  • 14. Relationship between cystathionine gamma-lyase gene polymorphism and essential hypertension in Northern Chinese Han population., Chinese medical journal, Li, Yun Y and 8 more authors.
  • 15. Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone., The Journal of biological chemistry, Majtan, Tomas T, Singh, Laishram R LR, Wang, Liqun L, Kruger, Warren D WD and Kraus, Jan P JP.
  • 16. MALDI-TOF MS genotyping of polymorphisms related to 1-carbon metabolism using common and mass-modified terminators., Clinical chemistry, Meyer, Klaus K, Fredriksen, Ase A and Ueland, Per Magne PM.
  • 17. Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S., The Journal of biological chemistry, Sun, Qingxiang Q and 10 more authors.
  • 18. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: a pathway-wide association study., Genetic epidemiology, Boyles, Abee L AL and 16 more authors.
  • 19. Large-scale proteomics and phosphoproteomics of urinary exosomes., Journal of the American Society of Nephrology : JASN, Gonzales, Patricia A PA and 7 more authors.
  • 20. An association study of 45 folate-related genes in spina bifida: Involvement of cubilin (CUBN) and tRNA aspartic acid methyltransferase 1 (TRDMT1)., Birth defects research. Part A, Clinical and molecular teratology, Franke, Barbara B and 7 more authors.
  • 21. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China., Environmental and molecular mutagenesis, Shen, Min M and 12 more authors.
  • 22. H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia., The Journal of biological chemistry, Chiku, Taurai T and 5 more authors.
  • 23. Variations in folate pathway genes are associated with unexplained female infertility., Fertility and sterility, Altmäe, Signe S and 7 more authors.
  • 24. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation., World journal of gastroenterology, Renga, Barbara B, Mencarelli, Andrea A, Migliorati, Marco M, Distrutti, Eleonora E and Fiorucci, Stefano S.
  • 25. Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies., Molecular genetics and metabolism, Kraus, Jan P JP and 14 more authors.
  • 26. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions., The Journal of biological chemistry, Singh, Sangita S, Padovani, Dominique D, Leslie, Rachel A RA, Chiku, Taurai T and Banerjee, Ruma R.
  • 27. PTEN identified as important risk factor of chronic obstructive pulmonary disease., Respiratory medicine, Hosgood, H Dean HD, Menashe, Idan I, He, Xingzhou X, Chanock, Stephen S and Lan, Qing Q.
  • 28. Genetic susceptibility to distinct bladder cancer subphenotypes., European urology, Guey, Lin T LT and 18 more authors.
  • 29. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip., American journal of human genetics, Talmud, Philippa J PJ and 38 more authors.
  • 30. Integrative predictive model of coronary artery calcification in atherosclerosis., Circulation, McGeachie, Michael M and 13 more authors.
  • 31. Cystathionine beta-synthase 844Ins68 polymorphism is not associated with the levels of homocysteine and cysteine in an Indian population., Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, Kumar, Jitender J, Garg, Gaurav G, Karthikeyan, Ganesan G and Sengupta, Shantanu S.
  • 32. The expression and activity of cystathionine-γ-lyase and 3-mercaptopyruvate sulfurtransferase in human neoplastic cell lines., Amino acids, Jurkowska, Halina H, Placha, Wojciech W, Nagahara, Noriuki N and Wróbel, Maria M.
  • 33. Ancient origin of the CTH alelle carrying the c.200C>T (p.T67I) variant in patients with cystathioninuria., Clinical genetics, Espinós, C C and 8 more authors.
  • 34. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study., Diabetes care, Bailey, Swneke D SD and 11 more authors.
  • 35. Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia., PloS one, Jugessur, Astanand A and 12 more authors.
  • 36. [Expression of cystathionine-γ-lyase/hydrogen sulfide pathway in CVB3-induced myocarditis in mice]., Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, Hua, Wang W and 6 more authors.
  • 37. Folate-metabolizing gene variants and pregnancy outcome of IVF., Reproductive biomedicine online, Laanpere, M M and 5 more authors.
  • 38. Specificity protein-1 as a critical regulator of human cystathionine gamma-lyase in smooth muscle cells., The Journal of biological chemistry, Yang, Guangdong G, Pei, Yanxi Y, Teng, Huajian H, Cao, Qiuhui Q and Wang, Rui R.
  • 39. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium., Briefings in bioinformatics, Gaudet, Pascale P, Livstone, Michael S MS, Lewis, Suzanna E SE and Thomas, Paul D PD.
  • 40. Expression of cystathionine β-synthase and cystathionine γ-lyase in human pregnant myometrium and their roles in the control of uterine contractility., PloS one, You, Xing-Ji XJ and 8 more authors.
  • 41. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells., Journal of cellular physiology, Yang, Guangdong G, Pei, Yanxi Y, Cao, Qiuhui Q and Wang, Rui R.
  • 42. H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response., Science signaling, Krishnan, Navasona N, Fu, Cexiong C, Pappin, Darryl J DJ and Tonks, Nicholas K NK.
  • 43. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells., Urology, Guo, Hui H and 5 more authors.
  • 44. Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines., Cellular signalling, Yin, Peng P and 12 more authors.
  • 45. H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase., Circulation, Kondo, Kazuhisa K and 14 more authors.
  • 46. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator., The American journal of pathology, Cindrova-Davies, Tereza T and 5 more authors.
  • 47. Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia., Circulation, Wang, Keqing K and 14 more authors.
  • 48. Regulation of cystathionine γ-lyase in mammalian cells by hypoxia., Biochemical genetics, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 49. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients., Breast cancer research : BCR, Chung, Suyoun S and 6 more authors.
  • 50. [Cystathionine γ-lyase]., Postepy higieny i medycyny doswiadczalnej (Online), Jurkowska, Halina H, Kaczor-Kamińska, Marta M, Bronowicka-Adamska, Patrycja P and Wróbel, Maria M.
  • 51. Decreased cystathionine-γ-lyase (CSE) activity in livers of type 1 diabetic rats and peripheral blood mononuclear cells (PBMC) of type 1 diabetic patients., The Journal of biological chemistry, Manna, Prasenjit P, Gungor, Neslihan N, McVie, Robert R and Jain, Sushil K SK.
  • 52. Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells., Mutation research, Pan, Yan Y and 5 more authors.
  • 53. The cystathionine γ-lyase/hydrogen sulfide system maintains cellular glutathione status., The Biochemical journal, Lee, Zheng-Wei ZW, Low, Yi-Lian YL, Huang, Shufen S, Wang, Tianxiao T and Deng, Lih-Wen LW.
  • 54. The binding site for the transcription factor, NF-κB, on the cystathionine γ-lyase promoter is critical for LPS-induced cystathionine γ-lyase expression., International journal of molecular medicine, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 55. Regulation of cystathionine gamma-lyase/H₂S system and its pathological implication., Frontiers in bioscience (Landmark edition), Zhao, Kexin K, Li, Hongzhu H, Li, Shuangshuang S and Yang, Guangdong G.
  • 56. Dysregulation of hydrogen sulphide metabolism impairs oviductal transport of embryos., Nature communications, Ning, Nannan N and 5 more authors.
  • 57. Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer., Cellular signalling, Fan, Kun K and 7 more authors.
  • 58. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression., Antioxidants & redox signaling, Shen, Yaqi Y and 7 more authors.
  • 59. Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression., Pigment cell & melanoma research, Panza, Elisabetta E and 11 more authors.
  • 60. A proteome-scale map of the human interactome network., Cell, Rolland, Thomas T and 69 more authors.
  • 61. Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase., Cell cycle (Georgetown, Tex.), Paul, Bindu D BD and Snyder, Solomon H SH.
  • 62. The importance of MTHFR, MTR, MTRR and CSE expression levels in Caucasian women with preeclampsia., European journal of obstetrics, gynecology, and reproductive biology, Seremak-Mrozikiewicz, Agnieszka A and 6 more authors.
  • 63. The importance of rs1021737 and rs482843 polymorphisms of cystathionine gamma-lyase in the etiology of preeclampsia in the Caucasian population., Ginekologia polska, Mrozikiewicz, Przemysław M PM and 8 more authors.
  • 64. Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids., American journal of physiology. Heart and circulatory physiology, Renga, Barbara B and 9 more authors.
  • 65. Correlation between the cystathionine-γ-lyase (CES) and the severity of peptic ulcer disease., African health sciences, Chen, Xiong X, Wan, Ying-Chun YC, Guo, Tao T, Xu, Can-Xia CX and Wang, Fen F.
  • 66. MPST but not CSE is the primary regulator of hydrogen sulfide production and function in the coronary artery., American journal of physiology. Heart and circulatory physiology, Kuo, Maggie M MM and 10 more authors.
  • 67. Transcriptional Regulation of Cystathionine-γ-Lyase in Endothelial Cells by NADPH Oxidase 4-Dependent Signaling., The Journal of biological chemistry, Mistry, Rajesh K RK and 8 more authors.
  • 68. LPS Up-Regulates Cystathionine γ -Lyase Gene Expression in Primary Human Macrophages via NF-κB/ERK Pathway., Inflammation & allergy drug targets, Badiei, Alireza A, Gieseg, Steven S, Davies, Sian S, Izani Othman, Mohd M and Bhatia, Madhav M.
  • 69. Radiation Exposure Promotes Hepatocarcinoma Cell Invasion through Epithelial Mesenchymal Transition Mediated by H2S/CSE Pathway., Radiation research, Pan, Yan Y, Zhou, Cuiping C, Yuan, Dexiao D, Zhang, Jianghong J and Shao, Chunlin C.
  • 70. Cystathionine γ-lyase(CSE)/hydrogen sulfide system is regulated by miR-216a and influences cholesterol efflux in macrophages via the PI3K/AKT/ABCA1 pathway., Biochemical and biophysical research communications, Gong, Duo D and 15 more authors.
  • 71. MicroRNA-186 promotes macrophage lipid accumulation and secretion of pro-inflammatory cytokines by targeting cystathionine γ-lyase in THP-1 macrophages., Atherosclerosis, Yao, Yan Y and 9 more authors.
  • 72. Cystathionine γ-lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis., Scientific reports, van den Born, J C JC and 5 more authors.
  • 73. Dichotomous effects of isomeric secondary amines containing an aromatic nitrile and nitro group on human aortic smooth muscle cells via inhibition of cystathionine-γ-lyase., Biochimie, Ji, Yajing Y and 6 more authors.
  • 74. Distinctive expression pattern of cystathionine-β-synthase and cystathionine-γ-lyase identifies mesenchymal stromal cells transition to mineralizing osteoblasts., Journal of cellular physiology, Gambari, Laura L and 6 more authors.
  • 75. Age-Dependent Allergic Asthma Development and Cystathionine Gamma-Lyase Deficiency., Antioxidants & redox signaling, Wang, Peipei P and 6 more authors.
  • 76. Augmented H2S production via cystathionine-beta-synthase upregulation plays a role in pregnancy-associated uterine vasodilation., Biology of reproduction, Sheibani, Lili L and 7 more authors.
  • 77. Total sulfane sulfur bioavailability reflects ethnic and gender disparities in cardiovascular disease., Redox biology, Rajpal, Saurabh S and 12 more authors.
  • 78. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides., Gene, Maruyama, K K and Sugano, S S.

Application Protocols

No validated or tested application protocols are provided in the Product Data for H3-CoA-20.

Item-specific recommended conditions, concentrations, or assay formats: Not specified for this item; refer to CoA/Spec Sheet.

General non-item-specific guidance for handling screening compounds:

• Stock preparation: Dissolve in anhydrous DMSO to a convenient concentration (e.g., 10–50 mM), vortex/sonicate if required, and sterile-filter if needed for cell-based assays.
• Aliquoting: Dispense single-use aliquots in inert, low-bind tubes or 384-well source plates; seal to minimize evaporation and moisture uptake.
• Assay dosing: Dilute into assay buffer or media to maintain consistent vehicle concentrations across wells; include vehicle-only controls and positive/negative assay controls.
• Data quality: Include counterscreens for aggregation, redox activity, and fluorescence interference; confirm hits with freshly prepared stocks from independent weighings or lots.

Biological Roles

Item-specific biological targets, pathways, or roles for H3-CoA-20 are not provided in the Product Data.

General considerations for screening compounds (non-item-specific):

• Potential roles assessed empirically include modulation of enzyme catalysis, receptor binding, ion channel function, or interference with protein–protein interactions. Assignment requires experimental validation and orthogonal confirmation.
• ADME-relevant properties (permeability, stability, efflux liability) are compound-specific and cannot be inferred without structure; perform permeability (e.g., PAMPA/MDCK), microsomal stability, and plasma protein binding only if your study requires such data.
• Assay interference risks: Some small molecules exhibit colloidal aggregation, redox activity, or fluorescence/absorbance overlap with assay readouts. Use aggregate-disrupting detergents, redox counterscreens, and spectral scans to de-risk hits.

Important note: H3-CoA-20 is designated “For research use only” and is not validated for diagnostic, therapeutic, or clinical applications.

Buffer Applications

No dedicated buffer system or pH specification is provided for H3-CoA-20. As a general practice for small-molecule assays:

• Preparation of working solutions (general guidance):
  • Make a concentrated stock in DMSO (e.g., 10–50 mM), then dilute into PBS, HEPES, or assay-specific buffers to achieve the desired final concentration while keeping DMSO typically ≤0.1–1% v/v.
  • If precipitation is observed upon dilution, consider adding 0.01–0.05% nonionic surfactant (e.g., Tween-20) or using a staged dilution with intermediate ACN/MeOH co-solvent (validate for assay compatibility).
• pH considerations: Without a known pKa, select buffers in the physiological range (pH 6.8–7.6) unless the assay requires otherwise; verify stability by LC at intended pH and temperature.
• Filtration: If particulate matter appears, filter through 0.2 µm PTFE (organic) or PES/RC (aqueous) membranes according to solvent composition.

Note: These are general best practices for small-molecule preparation and are not item-specific specifications for H3-CoA-20.

Green Alternatives

Because the solvent compatibility and use pattern of H3-CoA-20 are not specified, green chemistry considerations focus on general practices for small-molecule assay work.

• Prefer aqueous buffers when possible: Pre-dissolve in a minimal volume of DMSO, then dilute into HEPES/PBS to the lowest feasible DMSO percentage compatible with the assay.
• Solvent hierarchy (general, literature-based):
  • Greener: water, ethanol, isopropanol (as feasible and assay-compatible).
  • Use with care: acetonitrile, methanol, acetone.
  • Avoid or minimize: DMF, DMAc, NMP due to reproductive toxicity concerns, unless strictly required for solubilization during analytics.
• Micro-scale operations: Use low-volume plates (384/1536-well) and sealed reservoirs to reduce solvent use and emissions.
• Waste reduction: Consolidate organic waste streams; employ analytical LC methods with shorter gradients and lower flow rates where validated.

Trade-offs:

• Replacing DMSO with greener solvents may decrease solubility and assay consistency; validate signal windows and compound recovery.
• Surfactants and cyclodextrins can improve aqueous handling but may introduce assay artifacts—benchmark with appropriate controls.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or manufacturing use is provided for H3-CoA-20. This product is designated “For research use only.”

General context (non-item-specific):

• Screening compounds such as Moligand™ entries are commonly used in discovery research for target validation and SAR exploration but are not supplied under GMP, ICH, or compendial monographs.
• If translational or pre-formulation studies are contemplated, obtain comprehensive identity, purity, polymorph, and stability data from the supplier and perform independent verification under appropriate quality systems.
• Excipient or processing-aid roles are not applicable without explicit qualification and documentation; do not incorporate into products intended for human or veterinary use.

Physical Properties

Item-specific physicochemical properties are not provided in the Product Data for H3-CoA-20.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet. (General note: Moligand™ library members are commonly provided as solids or DMSO solutions; DMSO stocks at 10–50 mM are typical practice in screening labs—general information, not item-specific.)
• LogP/logD: Not specified for this item; refer to CoA/Spec Sheet.
• pKa: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index/UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.

General guidance for handling unknown small molecules (literature/good practice):

• Prepare analytical micro-scale solubility checks in DMSO, MeOH, ACN, PBS (with/without 0.01–0.1% Tween-20), and assay buffer, monitoring by visual inspection or UV/LC.
• If hygroscopicity is unknown, minimize exposure to ambient humidity and perform weighing rapidly in a desiccated environment.

Quality and Grades

Grade: Moligand™ (as listed in the Product Data).

• What Moligand™ commonly signifies (general information about the grade family, not a guarantee for this specific item):
  • Typically curated for small-molecule discovery workflows (e.g., primary screening, target deconvolution, chemoproteomics) where identity and gross purity are suitable for research assays.
  • Lots are often supported by orthogonal identity checks (e.g., LC–MS and/or NMR) and by nominal purity targets appropriate for screening libraries. Exact acceptance criteria, residual solvents, salt form, and purity thresholds are item- and lot-specific.
• Item-specific quality parameters for H3-CoA-20:
  • Purity: Not specified for this item; refer to CoA/Spec Sheet.
  • Stabilizers/inhibitors: Not specified for this item; refer to CoA/Spec Sheet.
  • Residual solvents, water content, metals, UV profile: Not specified for this item; refer to CoA/Spec Sheet.

Practical notes for screening-grade materials (general guidance):

• Verify identity and purity in-house before critical experiments (e.g., LC–MS, quantitative 1H NMR, or HPLC/UPLC-UV).
• Document salt/hydrate form and counterions; normalize dosing based on free-base/free-acid equivalent if applicable.
• For HTS/fragment/chemogenomic use, qualify lots in a small pilot assay to confirm performance and lack of assay interference.

Reaction and Applications

No specific synthetic or reaction-use applications are provided for H3-CoA-20. As a Moligand™ screening compound, it is primarily intended for discovery and assay workflows rather than as a synthetic reagent.

General research applications (non-item-specific):

• Biochemical/biophysical screening: Evaluate binding or activity in enzyme assays, receptor-ligand screens, or protein–protein interaction disruptor assays using DMSO stocks diluted into assay buffer.
• Cell-based assays: Test phenotypic responses at multiple concentrations with counter-screens for cytotoxicity and assay interference (e.g., redox cycling, aggregation, fluorescence quenching).
• Mechanism-of-action follow-up: If activity is observed, deploy orthogonal assays (SPR, DSF, thermal shift, ITC, CETSA) to characterize binding and stability effects.
• Chemoproteomics (if functional handles are present—structure dependent): Consider photoaffinity or clickable analog development only if structural information supports derivatization.

Practical tips (general):

• Confirm identity/purity prior to key assays (LC–MS/HPLC).
• Minimize freeze–thaw and light exposure until photostability and hydrolytic stability are known.
• Track final DMSO concentration and include vehicle controls; incorporate detergent at low levels to mitigate colloidal aggregation when relevant.

Reaction Conditions

No reaction conditions are specified for H3-CoA-20, and it is not provided as a synthetic reagent.

General guidance (non-item-specific) if derivatization is pursued after structure disclosure:

• Solvents: Choose based on functional groups (e.g., DMF/DMAc for polar couplings, toluene/THF/Me-THF for organometallic chemistry, ACN/MeOH for SN1/SN2 in polar media). Prefer greener options when feasible.
• Temperatures: 0–25°C for sensitive couplings; 60–120°C for robust cross-couplings under inert atmosphere; monitor by TLC/LC–MS.
• Catalysts/bases: Pd(0/II) with appropriate ligands for C–C/C–N couplings; carbodiimides/HATU/EDC for amidations; bases selected for pKa matching and functional group compatibility.
• Workup/purification: Quench carefully, extract with appropriate solvents, and purify by flash chromatography or preparative HPLC as dictated by polarity.

Note: These are general conditions and are not item-specific recommendations.

Safety and Handling

Hazard classification for H3-CoA-20 is not provided in the Product Data. Always consult the SDS for authoritative guidance.

• GHS classification: Not specified for this item; refer to SDS.
• Signal word and H-statements: Not specified for this item; refer to SDS.
• Pictograms: Not specified for this item; refer to SDS.

General laboratory precautions (good practice for screening compounds):

• PPE: Use lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., nitrile). Handle powders in a fume hood or ventilated enclosure to avoid inhalation.
• Avoid contact with skin/eyes; prevent aerosolization when reconstituting or aliquoting.
• Storage incompatibilities: Until structure is known, avoid strong oxidizers/reductants, strong acids/bases, and reactive metals. Keep away from ignition sources if volatility is suspected.
• First aid (overview; defer to SDS): Inhalation—move to fresh air; Skin—wash with soap/water; Eyes—rinse with water for several minutes; Ingestion—rinse mouth and seek medical attention.
• Spill response: For small spills, absorb with inert material (e.g., vermiculite), collect as chemical waste; avoid dry sweeping of powders—use damp disposable towels or HEPA vacuum designed for laboratory use.
• Waste: Dispose of according to institutional chemical waste procedures; segregate halogenated vs. non-halogenated organic waste if solvents are involved.

Solvent Selection

Item-specific solubility and polarity for H3-CoA-20 are not disclosed.

General solvent strategy for small-molecule screening compounds (literature/practice):

• Primary stock solvent: DMSO is the default due to broad solvency and assay compatibility. Start at 10–50 mM; filter if needed (PTFE, 0.2 µm) to remove particulates.
• Secondary cosolvents: MeOH, ACN, or DMF may assist initial dissolution prior to DMSO titration. For aqueous assays, dilute DMSO stocks into buffer keeping final DMSO ≤0.1–1% v/v as compatible with the assay.
• Aqueous compatibility enhancers: Low levels of Tween-20 (0.01–0.05%), Pluronic F-127, or cyclodextrins can enhance solubility of hydrophobes (assess assay interference).
• Avoid precipitation: Visual-check after dilution; use light scattering or analytical HPLC to confirm solubilization in assay buffer.

Quick comparison (general):

• DMSO: strongest solvency; may affect enzyme stability at >1–2%.
• MeOH/ACN: useful for analytics and co-solvency; higher toxicity/volatility than DMSO; typically limited to ≤1–5% in assays.
• PBS/HEPES buffers: preferred for biology but require pre-dissolution in organic solvent if compound is poorly water-soluble.

Storage and Reconstitution

Storage conditions (item-specific):

• Storage: Room temperature (as provided in the Product Data).
• Shipped in: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

General reconstitution guidance for small-molecule screening compounds (non-item-specific):

• Reconstitution solvent: Use anhydrous DMSO as primary solvent unless item-specific guidance indicates otherwise. Start at 10–50 mM stock.
• Technique: Warm gently to ambient temperature, vortex, and sonicate briefly if necessary. If insoluble, try co-solvents (MeOH/ACN) before finalizing in DMSO; verify solution clarity and homogeneity.
• Filtration: If particulate is present and solvent-compatible, filter through 0.2 µm PTFE for organic solutions or PES for aqueous dilutions.
• Aliquoting and stability: Prepare single-use aliquots to avoid repeated freeze–thaw. Protect from light until photostability is known. If storing DMSO stocks, keep tightly sealed and desiccated; many labs store at −20 to −80°C for long-term stability (general practice, not item-specific).

Always consult the item’s CoA/Spec Sheet and SDS for lot-specific stability, concentration limits, and handling precautions.

Structure and Identity

Brief overview: H3-CoA-20 is supplied as a Moligand™ screening compound. Structural identifiers for this specific item are not disclosed in the Product Data.

• Product name: H3-CoA-20 (SKU: rp174191)
• CAS: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Structural class: Not specified for this item; refer to CoA/Spec Sheet.

2D structure description (general guidance):

• Without a disclosed structure, functional groups, ring systems, and stereocenters cannot be enumerated. If structural data are provided in the accompanying CoA/Spec Sheet, identify: (a) heteroatoms and charge state, (b) aromatic vs. aliphatic domains, (c) H-bond donors/acceptors, (d) stereogenic centers or geometric isomers, and (e) any labile motifs (e.g., esters, thioesters).

Synthetic Utility

H3-CoA-20 is offered as a Moligand™ screening compound; no structure or functional group information is provided, so specific synthetic transformations cannot be recommended.

General notes (non-item-specific):

• If the structure becomes available and contains derivatizable handles (e.g., amines, carboxylates, halides, azides, alkynes), common transformations include amide coupling, nucleophilic substitutions, SuFEx, click reactions (CuAAC), and cross-couplings (Suzuki, Sonogashira, Buchwald–Hartwig).
• For probe development, incorporation of photoaffinity motifs (diazirine/benzophenone) or bioorthogonal tags (alkyne/azide) can enable chemoproteomics—contingent on SAR tolerability.
• Stability screening prior to synthesis: Assess hydrolysis (acid/base), redox sensitivity, and photolability to inform protecting-group and purification strategies.

Without item-specific structure, treat H3-CoA-20 as a terminal testing entity rather than a building block.

Target Specificity

No target, epitope, or specificity information is provided for H3-CoA-20 in the Product Data. There are no disclosed data on protein targets, binding sites, or selectivity profiles for this item.

For users investigating target engagement (general guidance):

• Employ orthogonal methods such as thermal shift assays (DSF), CETSA, SPR, ITC, or BRET to confirm binding and estimate affinity.
• Run selectivity panels relevant to your target class (e.g., kinase, GPCR, protease) to identify off-target interactions.

Item-specific target data: Not specified for this item; refer to CoA/Spec Sheet or associated screening reports if available.